
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026, 4:35 AM ET
Qureights Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial
Nasdaq: $CTNMClinical Biotechnology
CTNM Stock Hub: Contineum Therapeutics News, PIPE-791 and PROPEL-IPF
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for inflammatory and fibrotic diseases. Its lead asset PIPE-791, an LPA1 receptor antagonist, is in the global Phase 2 PROPEL-IPF trial in idiopathic pulmonary fibrosis. PIPE-307, an M1 receptor inhibitor, is developed by Johnson & Johnson under a global license. Third-quarter 2026 results show $244.5 million in cash and marketable securities and a runway through mid-2029.
Full research report · PDF
Contineum Therapeutics ($CTNM), research updated November 21, 2026
17 pages. For personal use only: redistribution prohibited.
Next milestone
Further PROPEL-IPF progress. The June 2028 date stated in the filing is an estimated study completion date.
CTNM stock at a glance
Chart analysis · JC
Technical chart analysis of $CTNM with bull and bear scenarios on JC Just Charts.
Where Contineum Therapeutics stands now
Contineum reported third-quarter 2026 results on November 3, disclosing $244.5 million in cash, cash equivalents and marketable securities at September 30 and a projected runway through mid-2029. The ongoing Phase 2 PROPEL-IPF study evaluates whether PIPE-791 can improve lung function in patients with idiopathic pulmonary fibrosis.
Constructive case
Cautious case
Latest Contineum Therapeutics news
Nov 9, 2026
Qureights fibrosis imaging biomarker selected by Contineum as secondary endpoint in PROPEL-IPF trial
Contineum Therapeutics selected the Qureights fibrosis imaging biomarker as a secondary endpoint in its Phase 2 PROPEL-IPF clinical trial.
Nov 3, 2026
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Cash, cash equivalents and marketable securities were $244.5 million as of September 30, 2026, which Contineum believes is sufficient to fund planned operations through mid-2029. Research and development expenses were $16.0 million, a 45 percent increase from the third quarter of 2025. General and administrative expenses were $5.0 million, a 26 percent increase, and the net loss was $18.7 million for the three months ended September 30, 2026, compared with $12.8 million for the third quarter of 2025.
Oct 29, 2026
Stifel Healthcare Conference presentation scheduled
The company announced a November 12 fireside chat at 8:40 a.m. Eastern. The presentation schedule does not itself promise a clinical data release.
Oct 29, 2026
PROPEL-IPF registry lists 103 study locations
The posted registry update lists 103 locations, recruiting study status and estimated primary completion in May 2028. Registry dates remain estimates rather than an announced topline date.
Oct 12, 2026
BMS reports mixed-dose ALOFT-IPF Phase 3 findings
Admilparant met the primary endpoint at 60 mg, while the 120 mg dose did not reach statistical significance. This is competitor evidence in the LPA1 class, not proof of PIPE-791 benefit.
Sep 14, 2026
Partnered MOONLIGHT-1 misses its primary endpoint
JNJ-5120/PIPE-307 did not meet the Phase 2 depression trial’s primary efficacy endpoint. Johnson & Johnson controls further development under the collaboration.
Catalyst calendar
- September 14, 2026 — MOONLIGHT-1 did not meet its primary efficacy endpoint.
- November 3, 2026 — Contineum reported third-quarter results and a PROPEL-IPF operating update.
- June 2028 — Estimated completion of PROPEL-IPF in the 10-Q.
Contineum Therapeutics deep dive: the full analysis
The Merlintrader Research Library collects our dated clinical biotechnology stock research reports.
01 Scenario Tests That Separate PIPE-791 From the PIPE-307 Option
Contineum’s equity story now rests on two assets with very different economic plumbing, and the third-quarter 2026 filings make the split unusually clean. PIPE-791 is wholly owned and funded by Contineum. PIPE-307 is developed at Janssen’s discretion under a global license and development agreement, so its value to Contineum is optional and milestone-weighted rather than operating. Any scenario work should therefore test the two programs separately rather than blending them into a single pipeline narrative.
The first company-specific test is cash adequacy against trial scope. Contineum closed September 30, 2026 with $244.5 million in cash, cash equivalents and marketable securities and states that this funds planned operations through mid-2029, roughly one year beyond the estimated completion of the IPF trial (Q3 2026 results). That runway claim is the single most load-bearing disclosure in the quarter. A useful stress test asks what quarterly burn would be required to exhaust the balance before PROPEL-IPF reads out. Third-quarter research and development expense of $16.0 million, up 45 percent year over year on PIPE-791 IPF activity, plus $5.0 million of general and administrative expense and an $18.7 million net loss, sets the current burn baseline (10-Q). If enrollment accelerates, site costs and drug supply scale with it, so the runway is sensitive to the pace of the ongoing Phase 2 trial rather than to a fixed budget.
PROPEL-IPF studies lung function in idiopathic pulmonary fibrosis. Established antifibrotic studies provide context for why lung-function change matters. Differences between studies limit direct comparisons.
The third test is the PIPE-307 option. Because Janssen develops PIPE-307 in its sole discretion, Contineum does not control timing, indication expansion or termination. The 10-Q explicitly flags reliance on Janssen to develop PIPE-307 for major depressive disorder or any other indication as a named risk. Scenario analysis should treat PIPE-307 cash flows as contingent and outside management’s operating control, and should ask what portion of enterprise value the market assigns to a program the company cannot advance on its own schedule.
02 How Contineum Earns Its Way: License Economics Versus Direct Development Spend
Contineum’s business model is a hybrid that is easy to misread. On one side it is a conventional clinical-stage sponsor that spends its own balance sheet on PIPE-791. On the other it holds a licensed asset, PIPE-307, where a large pharmaceutical partner bears development cost and Contineum’s economics arrive as milestones and royalties rather than as revenue from operations. The third-quarter 2026 filings show no product revenue line, which is consistent with a pre-commercial model where value accrues through clinical progress and partner events.
The direct-development side is where the cash actually moves. Research and development expense of $16.0 million in the three months ended September 30, 2026 rose 45 percent from the prior-year quarter, driven primarily by PIPE-791 IPF program costs and employee-related expenses (Q3 2026 results). General and administrative expense of $5.0 million rose 26 percent on stock-based compensation and headcount. Net loss of $18.7 million compares with $12.8 million a year earlier. The pattern is a company deliberately converting balance sheet into trial execution, and the 10-Q confirms the company believes existing resources fund planned operations through mid-2029 (10-Q).
The partnership side is structurally different. Under the global license and development agreement, Janssen Pharmaceutica NV, a Johnson & Johnson company, develops PIPE-307 in its sole discretion. That phrase carries real economic weight. Contineum does not book PIPE-307 trial costs, so partner progress does not consume the runway. It also means Contineum cannot force a timeline, choose indications or prevent a deprioritization decision. The 10-Q names reliance on Janssen and the restrictions in the license agreement among its principal risks. For modeling purposes, PIPE-307 should be treated as an option whose value depends on partner behavior, not on Contineum’s operating plan.
The termination question deserves explicit attention. Because development discretion sits with Janssen, a termination or deprioritization would remove future milestone and royalty potential without changing near-term cash burn, since Contineum is not funding that program. The asymmetry runs the other way for PIPE-791: every dollar of PROPEL-IPF spend is Contineum’s, and every delay extends the period over which that spend accumulates against a fixed runway. The business model therefore rewards investors who track two separate clocks, one set by Contineum’s own trial enrollment and one set by a partner’s internal portfolio decisions.
A final structural point concerns capital formation. With 39,265,813 total shares outstanding as of October 30, 2026, including 35,353,313 Class A and 3,912,500 Class B shares, the company retains a dual-class structure that concentrates voting influence (10-Q). For a company whose value depends on a single readout, the relevant financial question is not near-term revenue but whether the current cash balance and share count carry the program to that readout without a dilutive financing.
03 PROPEL-IPF: Trial Scope, Endpoint Design and the Cash It Consumes
The PROPEL-IPF registry describes an ongoing Phase 2 evaluation of PIPE-791 in idiopathic pulmonary fibrosis. The company reports that the study is underway. It has not reported a clinical result.
Clinical operations and monitoring require expenditure while the study is active. Further disclosures may show how opening sites and enrolling participants translate into measured progress and financial commitments.
The clinical rationale the company advances is class validation plus differentiation. Management cites more than 1,600 patients treated with LPA1 antagonists across completed trials and argues PIPE-791 offers a potentially favorable tolerability profile (Q3 2026 results). Tolerability is not a soft claim in this disease. Nintedanib’s pooled safety experience shows diarrhea adverse events in roughly half of treated patients versus 16.1 percent on placebo, a burden that shapes real-world persistence (Richeldi et al., 2020). A better-tolerated oral backbone is the commercial thesis, and PROPEL-IPF is the first controlled test of it.
The cash dimension is direct. Third-quarter research and development expense of $16.0 million reflects higher PIPE-791 IPF program costs, and the company attributes the 45 percent year-over-year increase primarily to that program (10-Q). With $244.5 million in cash, cash equivalents and marketable securities at September 30, 2026, the runway extends through mid-2029, about a year past estimated trial completion. The financial question is not whether the trial is funded but what enrollment pace does to the spend curve. More sites enrolling faster pulls cost forward, and the runway statement assumes a spending trajectory the company has not quantified publicly.
PROPEL-IPF remains in progress. The 10-Q estimates study completion in June 2028 and does not give a scheduled date for a topline announcement.
The PROPEL-IPF trial registry describes the study’s randomized comparison and primary endpoint. The company’s May pain study update concerns a distinct exploratory study. The two comparisons address different patient populations and cannot be pooled.
04 PIPE-307 and the Partner-Controlled Second Program
PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder. It is the second program in Contineum’s disclosure but the first in structural complexity, because Contineum does not run the trials. Under the global license and development agreement, Janssen Pharmaceutica NV develops PIPE-307 in its sole discretion, and the 10-Q lists reliance on Janssen to develop the asset for major depressive disorder or any other indication among the company’s named risks (10-Q).
The financial mechanics follow from that structure. Contineum does not consolidate PIPE-307 trial costs into its research and development line, which is why the $16.0 million third-quarter R&D figure is best read as a PIPE-791 number with employee costs layered on. Partner-funded development preserves the runway. It also means Contineum’s economic interest arrives as milestone payments and royalties contingent on decisions made inside another company’s portfolio review. The 10-Q flags restrictions contained in the license agreement as a risk factor, and those restrictions can shape everything from disclosure to transfer rights.
The termination question is the one that most affects how the second program should be valued. Because Janssen holds sole development discretion, a decision to pause, narrow or terminate the program would not trigger a Contineum cash outflow, but it would remove the milestone and royalty stream that underpins any sum-of-the-parts valuation. Investors cannot observe Janssen’s internal prioritization, and Contineum’s filings do not disclose a PIPE-307 timeline. The program should therefore be modeled as a contingent option with unobservable timing rather than as a scheduled catalyst.
There is a disclosure asymmetry worth noting. The third-quarter release describes PIPE-307 in a single sentence and provides no trial status, enrollment figure or expected data date (Q3 2026 results). By contrast, PROPEL-IPF receives site counts, country counts, patient targets, treatment duration and a named endpoint. That imbalance is rational for a company whose operating spend sits in PIPE-791, but it means public information on PIPE-307 is thin and any change in partner commitment would likely surface first in a Contineum filing rather than in a press release.
For financial analysis, the practical conclusion is that PIPE-307 should not be used to offset PIPE-791 risk. The two programs have different controllers, different cost bearers and different failure modes. PIPE-791 fails or succeeds on Contineum’s own trial execution and on a 26-week FVC delta. PIPE-307 advances or stalls on a partner’s discretion. The company’s cash position of $244.5 million and runway through mid-2029 are functions of the first program’s burn, while the second program’s value is a function of decisions Contineum does not make.
05 IPF Demand, the PROPEL-IPF Design, and What the Comparators Actually Show
Existing antifibrotic medicines can slow the loss of lung function, but fibrosis remains a progressive condition. Clinical context matters when assessing the sponsor’s intended role for a new investigational treatment.
Published nintedanib results describe lung function in a separate study population. Those results inform clinical context. They should be read independently from the ongoing PROPEL-IPF program.
PIPE-307 sits in a different economic universe. It is partnered with Janssen, a Johnson & Johnson company, and is also designated JNJ-89495120 and JNJ-5120. Under the license, J&J controls development choices, so Contineum’s exposure is contingent rather than operational. The MOONLIGHT-1 study in major depressive disorder completed enrollment of 105 adults and missed its primary efficacy endpoint, per the company’s September 14, 2026 release. Exploratory analyses are ongoing, and no efficacy claim should rest on unreported analyses. Separately, a completed VISTA Phase 2 studied relapsing-remitting multiple sclerosis, a different population with different endpoints, and its results cannot be transplanted onto MOONLIGHT-1. The practical read: PIPE-307 can generate future contingent revenue if J&J advances it, but it is not a scheduled cash payment and not an assured clinical progression. The partnership’s termination economics are governed by the license, and the 10-Q does not disclose a near-term milestone receipt tied to MOONLIGHT-1.
The unmet need case for PIPE-791 therefore rests on mechanism differentiation and tolerability rather than on an absence of approved therapy. Nintedanib’s pooled safety experience across six trials, including diarrhea rates above 48% in treated arms versus 16.1% on placebo, illustrates the tolerability gap a new agent could exploit (Lancaster et al., BMJ Open Respiratory Research, 2019). Whether PIPE-791 delivers on that gap is unknown until PROPEL-IPF reports. The trial’s 26-week primary endpoint is short relative to the 52-week registration-standard windows used for the approved agents, which compresses cost and timeline but limits the mortality-adjacent evidence a payer may eventually want.
06 The Official Event Calendar From September Through November 2026
The documented event sequence for Contineum over the past ten weeks is short and unusually consequential. On September 14, 2026, the company disclosed topline Phase 2 results for JNJ-5120/PIPE-307 in MOONLIGHT-1, reporting that the study missed its primary efficacy endpoint in 105 enrolled adults with major depressive disorder. On November 3, 2026, Contineum filed its Form 10-Q for the period ended September 30, 2026 and issued third-quarter results the same day, disclosing liquidity of $244.484 million, a Q3 net loss of $18.697 million, and a cash runway projection through mid-2029. On November 12, 2026, management presented at the Stifel 2026 Healthcare Conference, an investor appearance rather than a data event. As of November 21, 2026, that appearance is historical and carries no readthrough to trial outcomes.
The interpretation requires separating three event types that the calendar places close together. The MOONLIGHT-1 miss is a clinical event with a defined population and endpoint, and its consequences flow through the J&J partnership rather than through Contineum’s own operating plan. The Q3 filing is a financial event that resets the liquidity baseline and the runway statement. The Stifel appearance is a communication event with no evidentiary content beyond restating the prior two. Treating the conference as a catalyst would misread the calendar.
The forward calendar is thinner and less dated. PROPEL-IPF is active, with the November 3 release citing more than 100 sites in 16 countries, but the company has not announced a topline date. The 10-Q’s runway statement extends through mid-2029 and the issuer compares that runway with roughly one year beyond estimated trial completion. That construction supports a planned funding window rather than an exact results date, and it does not guarantee completion. The next next expected development is therefore the continuation of PROPEL-IPF enrollment and site activation, with the topline date pending. No regulatory action, advisory committee, or filing deadline appears in the documented record for the balance of 2026.
The sequencing also matters for how the market should weight the September miss against the November financial disclosure. The MOONLIGHT-1 result removed a near-term efficacy catalyst from the partnered program, while the Q3 filing confirmed that the company’s own spending is now concentrated on PIPE-791. The 45.4% year-over-year increase in Q3 research and development expense, to $15.985 million from $10.992 million, is attributed largely to PIPE-791 IPF work and people costs. That reallocation is the financial signature of the calendar: the partnered asset absorbed a clinical setback, and the unpartnered asset absorbed the budget.
One further calendar distinction deserves emphasis. The chronic pain Phase 1b topline reported in May 2026 is exploratory and is not a registrational pain efficacy result, nor is it cross-indication evidence for IPF. It belongs to a separate program and a separate readout. Bundling it with PROPEL-IPF in a catalyst calendar would overstate the evidentiary base for the lead asset. The documented calendar through November 21, 2026 contains one clinical miss, one financial reset, and one investor appearance, and the next dated clinical event remains unannounced.
07 Third-Quarter 2026 Income Statement and the Nine-Month Cash Bridge
The period ended September 30, 2026 produced a wider loss on higher operating expense, with the increase concentrated in research and development. The table below reconciles the quarter and the nine-month period against the prior-year comparatives, drawn from the Form 10-Q filed November 3, 2026 and the accompanying earnings release.
| Line item | Q3 2026 | Q3 2025 | Change | 9M 2026 | 9M 2025 |
|---|---|---|---|---|---|
| Research and development | $15.985 million | $10.992 million | +45.4% | $40.334 million | $38.767 million |
| General and administrative | $4.981 million | $3.940 million | +26.4% | $14.964 million | $12.177 million |
| Total operating expense | $20.966 million | $14.932 million | +40.4% | $55.298 million | $50.944 million |
| Net loss | $18.697 million | $12.792 million | +46.2% | $48.307 million | $44.822 million |
| Net loss per share | $0.49 | $0.45 | — | $1.28 | $1.68 |
The per-share comparison is the least intuitive line. Nine-month net loss rose $3.485 million while loss per share fell from $1.68 to $1.28, a function of the larger share count following the company’s equity issuance activity. The Q3 equity table shows 1,409,443 common shares issued under the at-the-market facility for $19.427 million in proceeds after accounting for amounts shown. That issuance should not be double counted within the nine-month financing figure of $21.923 million.
The cash bridge explains why liquidity fell modestly despite a large operating loss. Cash and equivalents ended at $75.198 million versus $75.603 million at December 31, 2025, while marketable securities fell to $169.286 million from $187.293 million. The combined liquidity of $244.484 million compares with $262.896 million at year-end, a decline of $18.412 million. Operating cash flow of negative $38.827 million was offset by positive investing cash flow of $16.499 million, reflecting securities maturities, and financing cash flow of $21.923 million. The arithmetic closes: $75.603 million minus $38.827 million plus $16.499 million plus $21.923 million equals $75.198 million. Investing movements shift the mix between cash and securities without changing total liquidity, which is why the headline cash line understates the balance sheet.
Two balance-sheet details support the operating picture. Prepaid and other current assets rose to $5.260 million from $5.021 million, and total assets fell to $256.988 million from $276.642 million, consistent with the liquidity drawdown. On the liability side, accounts payable fell to $0.641 million from $1.016 million and accrued expenses fell to $4.663 million from $6.387 million, while current lease liabilities rose to $2.724 million from $2.341 million. The accumulated deficit widened to $225.687 million from $177.380 million.
The runway statement is the key forward figure. Management projects cash through mid-2029, subject to plan. That projection is not efficacy guidance and is not a mechanical extrapolation of one quarter’s burn. The nine-month operating cash use of $38.827 million was actually lower than the prior-year $42.270 million despite the larger net loss, a gap explained by noncash charges and working-capital movements. Anyone annualizing Q3’s $20.966 million operating expense across eleven quarters would understate the runway, because the company’s own projection embeds planned spending changes.
08 Gross Margin Absence, the R&D Mix, and Expense Quality
Contineum reports no revenue and therefore no gross margin. The income statement begins at operating expense, and the quality of the result must be read through the composition of that expense rather than through a margin line. The Q3 research and development increase of $4.993 million, or 45.4%, is attributed in the filing largely to PIPE-791 IPF activity and people costs. The general and administrative increase of $1.041 million, or 26.4%, is attributed largely to share-based compensation and staffing. Those two attributions point in different directions for expense quality: the R&D increase is program-linked and therefore scalable with trial progress, while the G&A increase is partly noncash and partly structural headcount.
The nine-month comparison sharpens the mix. Research and development rose $1.567 million, or 4.0%, to $40.334 million, while general and administrative rose $2.787 million, or 22.9%, to $14.964 million. Over nine months the G&A growth rate exceeded the R&D growth rate, even though the third quarter alone showed the opposite pattern. That divergence is consistent with a first-half G&A build, including public-company costs and staffing, that preceded the PROPEL-IPF spending ramp. The third quarter is the more forward-looking signal because it captures the trial at scale, with more than 100 sites activated across 16 countries as of the November 3 release.
The R&D mix also carries a partnership dimension. PIPE-307 development is controlled by Janssen under the license, so Contineum’s own R&D line should not be read as funding that program’s pivotal path. The MOONLIGHT-1 miss on September 14, 2026 reduces the probability-weighted value of future contingent payments without a corresponding charge to Contineum’s operating expense. That asymmetry is a feature of the license structure: the company retains optionality on success and avoids the cost of failure, but it also cannot direct the program’s next step. The 10-Q does not disclose a scheduled milestone receipt, so the partnership should be modeled as a contingent call rather than a cash flow.
The quality question for the PIPE-791 spend is whether the current run rate is representative. Q3 R&D of $15.985 million annualizes to roughly $63.9 million, well above the nine-month average of $13.445 million per quarter. Site activation and enrollment costs typically front-load in a Phase 2, so some elevation is expected, but the company’s mid-2029 runway projection implies a spending path that is not a straight-line extrapolation of the third quarter. The gap between the annualized quarter and the runway-implied burn is the single most useful check on whether the projection is internally consistent.
Two noncash items affect the quality of the loss. Share-based compensation sits inside both the R&D and G&A lines and is the stated driver of part of the G&A increase. The accumulated deficit of $225.687 million against total assets of $256.988 million shows a company whose balance sheet is now predominantly liquidity, with minimal fixed assets and modest working-capital liabilities. That structure is typical of a clinical-stage issuer and means the expense quality question reduces to one variable: how efficiently the PIPE-791 spend converts into enrollment and, eventually, a 26-week FVC readout. The next next expected development is continued PROPEL-IPF site activation and enrollment, with the topline date pending.
09 Working Capital and the Composition of a $244.484 Million Liquidity Base
The balance sheet Contineum Therapeutics reported for the period ended September 30, 2026, is best read as a liquidity statement with a small operating tail. Cash and cash equivalents stood at $75.198 million against $75.603 million at December 31, 2025, while marketable securities fell to $169.286 million from $187.293 million, per the September 2026 Form 10-Q. The combined figure of $244.484 million is the relevant number for runway analysis. Treating the $75.198 million cash line as the company’s liquid resources understates the position by $169.286 million and misstates the year-to-date movement, which is a decline of $18.412 million in total liquidity rather than a near-flat cash balance.
The operating working capital accounts are modest in absolute terms and moved in a direction that flattered reported cash use. Prepaid and other current assets rose to $5.260 million from $5.021 million. Accounts payable fell to $0.641 million from $1.016 million and accrued expenses fell to $4.663 million from $6.387 million, a combined reduction of $2.099 million in short-term liabilities. Current lease liabilities rose to $2.724 million from $2.341 million. Total assets declined to $256.988 million from $276.642 million, a movement dominated by the securities portfolio rather than by any impairment or write-down disclosed in the filing.
Two features of this balance sheet matter for how the income statement should be weighted. First, the accumulated deficit rose to $225.687 million from $177.380 million, which is consistent with a company that has consumed capital continuously since inception and has no product revenue. Second, the absence of debt principal on the current liability schedule means the working capital position is not complicated by covenant compliance or amortization. The liquidity question for Contineum is therefore purely one of burn rate against a clinical calendar, not solvency against a lender.
The current study and planned follow-up bring operating commitments, while the balance sheet provides resources to meet those commitments. The company’s cash forecast depends on the spending plan.
The issuer projects cash runway through mid-2029, subject to its operating plan, and separately compares that runway with roughly one year beyond estimated trial completion. That construction is a planning window, not a results date. It implies the company expects to fund PROPEL-IPF to completion and retain a buffer, which is a statement about capital sufficiency rather than about the probability of a successful readout. The distinction matters because the balance sheet can be adequate and the trial can still fail. Working capital analysis answers whether Contineum can pay for the experiment, not whether the experiment will work.
10 Operating cash flow and reconciliation of the nine-month loss
The nine-month cash flow statement for the period ended September 30, 2026, shows operating cash flow of negative $38.827 million against negative $42.270 million in the comparable 2025 period, per the September 2026 Form 10-Q. That is an improvement of $3.443 million in operating cash use in a year when the income statement deteriorated. Nine-month net loss widened to $48.307 million from $44.822 million. The gap between a larger net loss and a smaller cash burn is the single most important reconciliation item in the filing, and it is explained by noncash charges and by the working capital movements described in the prior chapter.
| Cash flow line, nine months ended September 30 | 2026 | 2025 | Change |
|---|---|---|---|
| Operating cash flow | −$38.827 million | −$42.270 million | +$3.443 million |
| Investing cash flow | +$16.499 million | +$43.740 million | −$27.241 million |
| Financing cash flow | +$21.923 million | +$19.220 million | +$2.703 million |
| Net change in cash and equivalents | −$0.405 million | +$20.690 million | −$21.095 million |
| Cash and equivalents, period end | $75.198 million | $42.633 million | +$32.565 million |
The bridge from the December 31, 2025 cash balance of $75.603 million is arithmetic: $75.603 million minus $38.827 million plus $16.499 million plus $21.923 million equals $75.198 million. The investing inflow of $16.499 million is largely the net effect of maturities and purchases within the marketable securities portfolio. It is not a source of new capital and it does not increase total liquidity. A reader who treats the $16.499 million investing inflow as cash generation would conclude the company is closer to breakeven than the operating line supports. The correct reading is that Contineum converted securities to cash, and the $18.412 million decline in combined liquidity is the true measure of the period.
The financing inflow of $21.923 million requires care because the equity table discloses a third-quarter issuance of 1,409,443 common shares under an at-the-market facility for $19.427 million after accounting for amounts shown. That issuance falls inside the nine-month financing total and must not be added to it. The distinction between the $19.427 million gross proceeds figure and the $21.923 million nine-month financing line is a timing and composition question that the filing resolves at the statement level. Adding the two produces a figure that appears nowhere in the primary document.
The operating expense base that drives the burn is now weighted toward PROPEL-IPF. Third-quarter research and development expense was $15.985 million against $10.992 million, an increase of 45.4 percent, which the company attributes largely to the IPF program and to people costs. Third-quarter general and administrative expense was $4.981 million against $3.940 million, up 26.4 percent, attributed largely to share-based compensation and staffing. Combined third-quarter operating expense was $20.966 million against $14.932 million. Nine-month research and development was $40.334 million against $38.767 million and nine-month general and administrative was $14.964 million against $12.177 million, a combined $55.298 million against $50.944 million.
The quarterly acceleration is the forward-looking signal. A single quarter at $20.966 million annualizes to roughly $83.864 million, well above the nine-month run rate of approximately $73.731 million. If the third-quarter level persists, the $244.484 million liquidity base covers under three years of operating expense before any financing, which is shorter than the mid-2029 runway the issuer projects. The reconciliation between those two numbers depends on the company’s own expectation of spend cadence, and the filing does not provide a quarterly forecast. What the cash flow statement establishes is that the current burn is real, that it is funded, and that the funding has so far come from the balance sheet and the at-the-market facility rather than from operations.
11 Debt, Contractual Obligations, and the Terms That Actually Bind
Contineum carries no funded debt on the balance sheet as of September 30, 2026. The current liability schedule in the September 2026 Form 10-Q lists accounts payable of $0.641 million, accrued expenses of $4.663 million, and current lease liabilities of $2.724 million. There is no short-term borrowings line, no current portion of long-term debt, and no disclosed credit facility drawn balance. The obligations that bind the company are therefore operating in character: lease commitments, accrued compensation and trial costs, and the contractual terms of its license with Janssen Pharmaceutica NV.
| Obligation category | Amount at September 30, 2026 | Nature |
|---|---|---|
| Accounts payable | $0.641 million | Trade, current |
| Accrued expenses | $4.663 million | Compensation, trial accruals, current |
| Current lease liabilities | $2.724 million | Facilities, current portion |
| Funded debt | None disclosed | No borrowings on the filing |
| Potential Janssen milestone receipts | Approximately $1 billion maximum under the terms | Contingent receipts to Contineum. Royalties are distinct |
The lease liability rose to $2.724 million from $2.341 million at December 31, 2025, a $0.383 million increase consistent with a facilities commitment rather than a financing decision. The absence of debt is a genuine structural advantage in the current environment because it removes covenant triggers and maturity walls from the liquidity discussion. It also means the company has no lender relationship to renegotiate if the PROPEL-IPF timeline extends. The only external capital lever disclosed is equity issuance, which is the subject of the next chapter.
The Janssen relationship is the obligation that carries the most economic weight and the least balance sheet visibility. PIPE-307, also designated JNJ-89495120 and JNJ-5120, is licensed to Janssen, and Johnson & Johnson controls development choices under the agreement. The September 14, 2026 company release reported that MOONLIGHT-1, a Phase 2 trial in major depressive disorder, completed enrollment of 105 adults per the 10-Q and missed its primary efficacy endpoint. Exploratory analyses are ongoing, and no efficacy claim should rest on analyses that have not been reported. The license can generate contingent revenues if future development succeeds. It is not a scheduled cash payment and it is not an assured clinical progression. A reader should not model milestone receipts from a program whose most recent controlled readout did not meet its primary endpoint.
The distinction between PIPE-307 and PIPE-791 is the central economic fact of this filing. PIPE-791 in PROPEL-IPF is company-controlled, company-funded, and consumes the operating expense that drives the burn. PIPE-307 is partner-controlled, partner-funded at the development level, and represents optionality rather than a cost center. The termination economics of the Janssen license are not separately disclosed, and the filing does not quantify contingent consideration. What can be said is that a termination by either party would remove a contingent revenue stream without reducing Contineum’s current operating expense, because that expense is concentrated in the IPF program. The partnership is asymmetric: it offers upside that is not on the balance sheet and it imposes no disclosed cash obligation that appears in the liability schedule.
The chronic pain Phase 1b program is a third and separate obligation. The May 2026 sponsor topline release described exploratory data, not a registrational pain efficacy result, and it should not be read as cross-indication evidence for either PIPE-791 or PIPE-307. The VISTA Phase 2 trial was conducted in relapsing-remitting multiple sclerosis and its population and outcome must never be attributed to MOONLIGHT-1. These separations are not pedantic. They determine which program the $20.966 million quarterly operating expense is actually buying, and the answer is overwhelmingly PROPEL-IPF.
Janssen paid Contineum $50 million upfront in 2023. The 10-Q describes future milestone and royalty rights that depend on development, commercialization and sales. The maximum is neither current cash nor a debt obligation of Contineum.
12 Share Issuance, Dilution, and What the At-the-Market Facility Has Already Done
As of October 30, 2026, Contineum had 39,265,813 total shares outstanding, comprising 35,353,313 shares of Class A common stock and 3,912,500 shares of Class B common stock, per the cover page of the September 2026 Form 10-Q. The dual-class structure concentrates voting control in the Class B shares while the Class A shares carry the economic and trading exposure under the CTNM symbol. For dilution analysis, the total share count is the correct denominator because both classes participate in earnings and losses, and the filing reports loss per share on that combined basis.
The dilution that has already occurred is documented in the equity table. During the third quarter, the company issued 1,409,443 common shares under an at-the-market facility for $19.427 million after accounting for amounts shown. That is a realized dilution event, not a shelf authorization. It contributed to the $21.923 million nine-month financing inflow and it is the reason the financing line is positive in a year with no debt issuance. The implied average price is approximately $13.78 per share on the gross proceeds figure, though the filing’s “after accounting for amounts shown” language means the net figure and the exact per-share economics should be read from the equity statement rather than derived.
The loss per share lines show the mechanical effect of that issuance. Third-quarter net loss was $18.697 million against $12.792 million, or $0.49 against $0.45 per share. The absolute loss grew 46.2 percent while the per-share loss grew 8.9 percent, and the difference is the larger share count absorbing part of the increase. For the nine months, net loss was $48.307 million against $44.822 million, or $1.28 against $1.68 per share. The nine-month per-share loss fell even as the absolute loss rose, which is the arithmetic signature of a materially larger share base in 2026 than in 2025. A reader comparing the two per-share figures without the share count would draw the wrong conclusion about the direction of the business.
Management’s cash forecast assumes a specific operating plan. Changes in trial spending or scope can alter funding needs and should be considered separately from the latest quarterly expense figure.
The at-the-market facility can support the company-controlled PIPE-791 program, including the ongoing PROPEL-IPF trial. PIPE-307 is controlled by Janssen under a license agreement with a separate set of potential payments. The MOONLIGHT-1 miss reported in September 2026 reduced the near-term case for the partnered asset without changing the spending obligations on the company-controlled IPF trial. Shareholders therefore face different risks in the two programs: Contineum bears the costs of advancing its own program, while the value of the licensed program depends on decisions by its partner.
The accumulated deficit of $225.687 million against total assets of $256.988 million frames the constraint. Equity has funded the deficit to date, and further equity is the disclosed mechanism for funding it forward. The relevant question for a reader is not whether dilution will occur but at what price relative to the clinical calendar, and the filing provides the share count, the realized issuance, and the runway projection without providing a price commitment. The Stifel appearance on November 12, 2026, is a historical investor event as of November 21, 2026, and should be distinguished from any trial or regulatory readout. No announced milestone date beyond the issuer’s runway projection appears in the primary documents, and the timing of PROPEL-IPF completion is pending.
13 Ownership Concentration and the Governance Levers Behind the PIPE-791 Decision
Contineum’s ownership structure matters less for its vote count than for what it implies about who bears the cost of the PROPEL-IPF decision. The September 2026 Form 10-Q reports 39,265,813 total shares outstanding as of October 30, 2026, split between 35,353,313 Class A shares and 3,912,500 Class B shares. The dual-class structure concentrates voting power in a small holder group even though the public float sits entirely in Class A. That arrangement is standard for venture-backed biopharma, but it means minority holders cannot force a strategic pivot if PROPEL-IPF disappoints.
The governance question that actually moves the financial analysis is capital allocation authority. The company raised $19.427 million through its at-the-market facility during the third quarter, issuing 1,409,443 Class A shares, per the September 2026 Form 10-Q. That is a board-level decision executed without a shareholder vote, and it is the mechanism by which the mid-2029 runway projection is defended. Investors should read the ATM as a standing option rather than a one-time event. The same shelf capacity remains available, and the pace of future issuance will be set by the same insiders who control the Class B votes.
Board composition and committee structure are disclosed in the annual proxy rather than the quarterly filing, so the November 21, 2026 evidence base does not support claims about specific director independence ratios. What the 10-Q does establish is that the company remains a smaller reporting company and an emerging growth company, which reduces disclosure frequency and exempts it from certain auditor attestation requirements. For a company whose entire equity story rests on one Phase 2 readout, lighter disclosure obligations raise the information asymmetry between insiders and public holders.
The practical governance read is narrow. Insiders control the ballot, the ATM controls the dilution path, and the accumulated deficit of $225.687 million as of September 30, 2026, versus $177.380 million at December 31, 2025, quantifies how much prior capital has already been consumed. Any future financing decision will be made by the same group, and the September 2026 Form 10-Q confirms no mechanism exists for public holders to block it. That is not a criticism of the structure. It is a statement about where decision rights sit when the PROPEL-IPF data arrive.
14 Competitive Evidence, Counterparties and What the Trials Actually Test
Contineum directly sponsors development of PIPE-791 in idiopathic pulmonary fibrosis. Janssen leads the partnered PIPE-307 program. Conclusions on one asset or indication do not determine the outcome of the other.
Lung-function results published for approved therapies help explain why the disease remains an active area of research. They provide no estimate of the outcome of Contineum’s current study.
PIPE-307 is a separate asset with a separate counterparty. It is partnered with Janssen, a Johnson & Johnson company, and carries the designations JNJ-89495120 and JNJ-5120. Janssen controls development choices under the license. The MOONLIGHT-1 trial completed enrollment of 105 adults and missed its primary efficacy endpoint, per the September 14, 2026 company release. Exploratory analyses are ongoing and no efficacy claim should rest on unreported analyses. The separately completed VISTA Phase 2 trial enrolled a relapsing-remitting multiple sclerosis population and must never be conflated with MOONLIGHT-1.
The economics of the Janssen relationship are contingent. Future development success could generate milestone and royalty revenue. The license is not a scheduled cash payment and does not assure clinical progression. Termination provisions sit in the license agreement, and the September 2026 Form 10-Q does not disclose a near-term termination trigger. The honest framing is that PIPE-307 contributes optionality with a counterparty that holds the decision rights, while PIPE-791 carries the company’s own capital and its own binary risk.
15 Cash, Burn and the Arithmetic of the Mid-2029 Runway
The balance sheet as of September 30, 2026, shows $75.198 million in cash and equivalents and $169.286 million in marketable securities, a combined liquidity position of $244.484 million, per the September 2026 Form 10-Q. The comparable figure at December 31, 2025, was $262.896 million, a decline of $18.412 million. Total assets fell to $256.988 million from $276.642 million over the same span.
The cash bridge reconciles cleanly. Starting cash of $75.603 million, minus $38.827 million of operating cash use, plus $16.499 million from investing, plus $21.923 million from financing, lands at $75.198 million. The investing inflow reflects securities maturities and shifts the mix between cash and securities without changing total liquidity. Readers who treat the $75.198 million cash line as the whole story will understate available capital by roughly $169 million.
Operating expense is the pressure point. Third-quarter research and development reached $15.985 million against $10.992 million a year earlier, up 45.4 percent, driven largely by PIPE-791 IPF activity and personnel. General and administrative expense rose to $4.981 million from $3.940 million, up 26.4 percent, on share-based compensation and staffing. Total third-quarter operating expense was $20.966 million versus $14.932 million. The net loss was $18.697 million, or $0.49 per share, against $12.792 million, or $0.45 per share.
The nine-month picture is more moderate. Research and development totaled $40.334 million versus $38.767 million, and general and administrative expense $14.964 million versus $12.177 million, for a combined $55.298 million against $50.944 million. Nine-month operating cash use was $38.827 million versus $42.270 million, an improvement that coexists with a larger net loss of $48.307 million because of noncash and working-capital movements. The accumulated deficit of $225.687 million quantifies cumulative consumption.
The issuer projects cash runway through mid-2029, subject to plan, and compares that window with roughly one year beyond estimated trial completion. That is a planning statement, not efficacy guidance and not a mechanical extrapolation of one quarter. At a third-quarter operating expense run rate near $21 million, the $244.484 million liquidity base covers roughly eleven to twelve quarters before any further ATM issuance. The $19.427 million raised in the third quarter shows the company is willing to use that lever, and each additional issuance extends the runway while diluting existing holders.
16 Forward Milestones and the Outcomes That Would Move the Thesis
Measurable outcomes fall into three buckets. The first is enrollment velocity. The November release cited more than 100 active sites in 16 countries, which is a capacity statement. The conversion of that footprint into randomized participants is the variable that determines whether the readout lands inside the funded window. The second is the FVC result itself, read against the placebo decline documented by Richeldi and colleagues in BMC Pulmonary Medicine in 2020. A separation from that benchmark with acceptable tolerability would be the single most consequential data point in the company’s history. The third is safety, which the same literature establishes as a genuine constraint in this indication.
On the partnered side, the measurable outcome is Janssen’s decision on PIPE-307 following the MOONLIGHT-1 miss reported September 14, 2026. Exploratory analyses are ongoing. Any announcement of a new study, a discontinuation, or an amendment to the license terms would be material, and the counterparty controls that timing. The September 2026 Form 10-Q does not commit Janssen to a date.
Financially, the observable milestones are quarterly operating expense and ATM usage. Third-quarter operating expense of $20.966 million and the $19.427 million raised under the ATM are the two numbers to track. A rising expense line paired with accelerating issuance compresses the runway faster than the mid-2029 projection implies. A stable expense line with no further issuance extends it.
The Stifel appearance on November 12, 2026, is historical as of November 21, 2026, and constitutes an investor conference appearance rather than a data event. It should not be read as a readout signal. The distinction between announced appearances and actual trial or regulatory disclosures is the discipline this program demands.
Merlintrader Health Score · $CTNM
3.00 out of 5
Assessed November 21, 2026. Merlintrader calculation: 4.00 × 30% + 3.00 × 30% + 2.00 × 20% + 2.00 × 10% + 3.00 × 10% = 3.00 out of 5.
Red flags to track
- MOONLIGHT-1 missed its primary efficacy endpoint per the September 14, 2026 release, and exploratory analyses remain unreported.
- Janssen controls PIPE-307 development decisions under the license, so Contineum cannot set that program’s timeline.
- Third-quarter research and development expense rose 45.4 percent year over year, concentrated in PIPE-791 IPF activity.
- The mid-2029 runway projection is a plan subject to change, not a mechanical extrapolation of one quarter.
- Dual-class structure leaves public holders without a practical vote on capital allocation or strategy.
- No PROPEL-IPF enrollment count has been disclosed, so site footprint is the only visible progress metric.
CTNM Stock FAQ: Contineum Therapeutics Questions Answered
What is the latest reporting period end date for Contineum?
September 30, 2026, per the Form 10-Q filed November 3, 2026.
How much liquidity did Contineum hold at September 30, 2026?
$244.484 million, comprising $75.198 million in cash and equivalents and $169.286 million in marketable securities.
What is the PROPEL-IPF primary endpoint?
The trial assesses lung-function change. The study has not produced a reported outcome.
Did PIPE-307 succeed in MOONLIGHT-1?
No. The trial completed enrollment of 105 adults and missed its primary efficacy endpoint per the September 14, 2026 company release.
Is VISTA the same trial as MOONLIGHT-1?
No. VISTA was a separate Phase 2 trial in relapsing-remitting multiple sclerosis and should not be conflated with MOONLIGHT-1.
How much did Contineum raise under its ATM in the third quarter?
$19.427 million from the issuance of 1,409,443 Class A shares.
When does Contineum say its cash lasts?
Through mid-2029, subject to plan, which the issuer compares with roughly one year beyond estimated trial completion.
Has Contineum announced a PROPEL-IPF results date?
No. The date is pending, and the company has disclosed site count rather than enrollment figures.
Sources and scientific literature
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CTNM or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biopharmaceutical companies face clinical, regulatory, manufacturing, reimbursement, commercialization and financing risks, including dilution. Results from development programs may not translate into approval or commercial performance. Investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



